SCHEMBL7721500

SCHEMBL7721500

CCc1nc2ccccc2n1C(C)C

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 2/20 0.63
▸ MEN1 O00255 2/20 0.58
▸ KMT2A Q03164 2/20 0.58
▸ TSHR P16473 3/20 0.58
▸ MAPK1 P28482 1/20 0.58
▸ ALDH1A1 P00352 4/20 0.56
▸ LMNA P02545 2/20 0.56
▸ HSD17B10 Q99714 1/20 0.53
▸ KDM4E B2RXH2 3/20 0.53
▸ HPGD P15428 2/20 0.51
▸ MAPT P10636 1/20 0.51
▸ RECQL P46063 1/20 0.50
▸ NPC1 O15118 1/20 0.50
▸ TP53 P04637 1/20 0.50
▸ GLA P06280 1/20 0.50
▸ GAA P10253 1/20 0.50
▸ RAB9A P51151 1/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ L3MBTL1 Q9Y468 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL859096 0.84 POLB (0.61) POLBMEN1KMT2ATSHRALDH1A1
SCHEMBL103328 0.84 POLB (0.61) POLBMEN1KMT2ATSHRALDH1A1
SCHEMBL859880 0.84 POLB (0.61) POLBMEN1KMT2ATSHRALDH1A1
SCHEMBL20088741 0.81 POLB (0.71) POLBMEN1KMT2ATSHRALDH1A1
SCHEMBL9570011 0.81 POLB (0.58) POLBMEN1KMT2ATSHRALDH1A1
SCHEMBL9597754 0.81 ALDH1A1 (0.60) POLBMEN1KMT2ATSHRALDH1A1
SCHEMBL7264500 0.79 MEN1 (0.49) POLBMEN1KMT2ATSHRMAPK1
SCHEMBL20088737 0.78 USP2 (0.55) POLBMEN1KMT2ATSHRMAPK1
SCHEMBL21142712 0.78 POLB (1.00) POLBMEN1KMT2ATSHRKDM4E
SCHEMBL28959783 0.78 POLB (0.58) POLBMEN1KMT2ATSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3277687-B1 7-(MORPHOLIN-4-YL)PYRAZOLE[1,5-A]PYRIMIDINE DERIVATIVES WHICH ARE USEFUL FOR THE TREATMENT OF IMMUNE OR INFLAMMATORY DISEASES OR CANCER Celon Pharma Sa (PL) 2019-10-30 — — EP disclosed
US-20190198781-A1 ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE SAME LUMINESCENCE TECHNOLOGY CORPORATION (TW) 2019-06-27 — — US disclosed
US-20180111939-A1 7-(MORPHOLIN-4-YL)PYRAZOLE[1,5-A]PYRIMIDINE DERIVATIVES WHICH ARE USEFUL FOR THE TREATMENT OF IMMUNE OR INFALMMATORY DISEASES OR CANCER CELON PHARMA S.A. (PL) 2018-04-26 — — US disclosed
US-20180111939-A1 7-(MORPHOLIN-4-YL)PYRAZOLE[1,5-A]PYRIMIDINE DERIVATIVES WHICH ARE USEFUL FOR THE TREATMENT OF IMMUNE OR INFALMMATORY DISEASES OR CANCER CELON PHARMA S.A. (PL) 2018-04-26 — — US disclosed
US-7638530-B2 1-{1-[4-(3-amino-5-phenyl-1H-pyrazolo[3,4-b]pyridin-6-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one; anticarcinogenic agents MERCK & CO., INC. (US) 2009-12-29 — — US disclosed
US-6875765-B2 Arylsulfonamide ethers, and methods of use thereof WARNER-LAMBERT COMPANY (US) 2005-04-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190198781-A1 ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE SAME SLCO4C1, PIEZO1, TRPC6 POLB 998/4885MEN1 1303/4885KMT2A 3652/4885
US-20180111939-A1 7-(MORPHOLIN-4-YL)PYRAZOLE[1,5-A]PYRIMIDINE DERIVATIVES WHICH ARE USEFUL FOR THE TREATMENT OF IMMUNE OR INFALMMATORY DISEASES OR CANCER AFF2, INF2, AFF1 POLB 3260/4885MEN1 194/4885KMT2A 3221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback